{"id":921582,"date":"2025-12-19T15:04:55","date_gmt":"2025-12-19T20:04:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cbdmd-inc-announces-closing-of-2-25-million-series-c-preferred-stock-private-placement\/"},"modified":"2025-12-19T15:04:55","modified_gmt":"2025-12-19T20:04:55","slug":"cbdmd-inc-announces-closing-of-2-25-million-series-c-preferred-stock-private-placement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cbdmd-inc-announces-closing-of-2-25-million-series-c-preferred-stock-private-placement\/","title":{"rendered":"cbdMD, Inc. Announces Closing of $2.25 Million Series C Preferred Stock Private Placement"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n CHARLOTTE, N.C.<\/span>, Dec. 19, 2025<\/span> \/PRNewswire\/ — cbdMD, Inc. (NYSE American: YCBD), a leading wellness company and the parent of Herbal Oasis THC seltzers, ATRx functional mushroom supplements, and Paw CBD, today announces that it has entered into securities purchase agreements with institutional investors whereby Company issued the investors an aggregate of 1,000,000 shares of Series C Convertible Preferred Stock in consideration of gross proceeds to the Company of $2.25 million. The Company intends to use the net proceeds of approximately $2.1 million for working capital general corporate purposes and support ongoing strategic initiatives. The Series C shares have a 10% annual dividend and are convertible at the option of the holder into the Company’s common stock at an initial conversion price of $2.25 per share, subject to certain anti-dilution protection provisions, with rights and preferences substantially the same as the Company’s issued and outstanding Series B Convertible Preferred Stock.<\/p>\n

\n

\n
\n \"cbdMD
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“We are pleased to continue strengthening our balance sheet to assist the Company’s ongoing initiatives to expand distribution for its consumer brands, and position cbdMD for sustained profitability,” said Ronan Kennedy, Chief Executive Officer and Chief Financial Officer of cbdMD.<\/p>\n

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/p>\n

\n About cbdMD, Inc.<\/b>\n <\/p>\n

cbdMD, Inc. (NYSE American: YCBD) is a leading wellness company offering a comprehensive line of U.S.-produced, hemp-derived cannabinoid products, including CBD, CBG, CBN, and more. Its brands include:<\/p>\n